<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6646">
  <stage>Registered</stage>
  <submitdate>23/05/2016</submitdate>
  <approvaldate>23/05/2016</approvaldate>
  <nctid>NCT02782663</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects With Crohn's Disease</studytitle>
    <scientifictitle>A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects With Crohn's Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-003759-23</secondaryid>
    <secondaryid>M14-327</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Crohn's Disease (CD)</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Crohn's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-494

Experimental: ABT-494 Dose A - Open label dose A once daily (QD)

Experimental: ABT-494 Dose B - Open label dose B QD


Treatment: drugs: ABT-494
Oral use

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of participants achieving Remission - It is defined as the proportion of participants achieving clinical remission and endoscopic remission.</outcome>
      <timepoint>Up to Month 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants in Remission at Week 0 who maintain remission - Remission is defined as participants achieving clinical remission and endoscopic remission.</outcome>
      <timepoint>Up to Month 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving Response - It is defined as the proportion of participants achieving clinical response and endoscopic response.</outcome>
      <timepoint>Up to Month 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving Clinical remission over time - Clinical remission is defined based on the patient reported outcomes: average daily stool frequency and average daily abdominal pain.</outcome>
      <timepoint>Up to Month 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving Clinical response over time - Clinical response is defined as change from baseline in the patient reported outcomes: average daily stool frequency and average daily abdominal pain.</outcome>
      <timepoint>Up to Month 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving Endoscopic remission - Endoscopic remission is based on Simplified Endoscopic Score for Crohn's disease.</outcome>
      <timepoint>Up to Month 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants in Endoscopic remission at Week 0 who maintain Endoscopic remission - Endoscopic remission is based on Simplified Endoscopic Score for Crohn's disease.</outcome>
      <timepoint>Up to Month 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving Endoscopic response - Endoscopic response is based on changes from baseline on the Simplified Endoscopic Score for Crohn's disease.</outcome>
      <timepoint>Up to Month 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving Crohn's Disease Activity Index (CDAI) remission - It is defined as CDAI less than 150.</outcome>
      <timepoint>Up to Month 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving Crohn's Disease Activity Index (CDAI) response - CDAI response is defined as a reduction in CDAI by &gt;= 70 from baseline of Study M13-740</outcome>
      <timepoint>Up to Month 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving Inflammatory Bowel disease Questionnaire (IBDQ) remission - IBDQ remission is defined as IBDQ &gt;= 170.</outcome>
      <timepoint>Up to Month 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving IBDQ response - IBDQ response is defined as an increase in IBDQ score &gt;= 16 point from Baseline of Study M13-740</outcome>
      <timepoint>Up to Month 96</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participant must have completed Study M13-740 through Week 52.

          -  If female, participant must be postmenopausal, surgically sterile or on using a birth
             control method.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  For any reason participant is considered by the investigator to be an unsuitable
             candidate

          -  Female participant with a positive pregnancy test at Baseline or who is considering
             becoming pregnant during the study.

          -  Participant is not in compliance with prior and concomitant medication requirements
             and procedures throughout Study M13-740.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>18/05/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>210</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>28/12/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Edmonton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vaughan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hvidovre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Amiens Cedex 01</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre Les Nancy Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Zerifin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bolonga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catanzaro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara, jud. Timis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Nitra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Presov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Ferrol, A Coruna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Headington, Oxford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a open-label extension (OLE) study designed to evaluate the long-term efficacy,
      safety, and tolerability of ABT-494.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02782663</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ana Lacerda, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>